CTVA
FY2026 Q1 · Calendar Q2 2026
Corteva, Inc.
Corteva delivered a strong start to fiscal 2026, beating consensus on both EPS ($1.50 vs. $1.17 estimate, 28% surprise) and revenue ($4.91B vs. $4.64B estimate, 5.7% surprise). Q1 EBITDA grew 21% year-over-year with margins above 29%, driven by solid performance across both seed and crop-protection segments. The company reaffirmed its full-year 2026 operating EBITDA guidance of $4.0 to $4.2B with 22 to 23% margins. A notable milestone: Corteva now expects to achieve royalty positivity this year, ahead of its prior royalty-neutral timeline, thanks to the Bayer licensing agreement. The planned separation into Vylor (seed) and a standalone crop-protection business remains on track for Q4 2026, with a Form 10 filing expected by Q2. Despite the strong quarter, the stock sold off post-earnings with a -3.9% abnormal move and -5.3% subsequent drift, potentially reflecting concerns over H2…
EPS surprise+28.2%
Market move-2.5%
